Aurobindo Pharma ₹800 Cr Buyback at ₹1,475 Approved

Hyderabad-based pharmaceutical major Aurobindo Pharma Limited announced on Monday that its board of directors has approved a share buyback worth up to ₹800 crore, marking the company's second significant capital-return initiative in under two years. The decision was taken at a board meeting held on April 6, 2026, convened under Regulation 29 of SEBI Listing Regulations.

Buyback Structure and Regulatory Compliance

The repurchase will be conducted through the tender offer route, in compliance with SEBI (Buy-Back of Securities) Regulations, 2018, and the Companies Act, 2013. All equity shareholders and beneficial owners registered as of the record date, including promoters and promoter group entities, will be eligible to participate on a proportionate basis.

The buyback size of ₹800 crore equals 3.93% of the company's total funds on a standalone basis and 2.62% on a consolidated basis, based on the latest financial statements as of March 31, 2025. The total buyback amount excludes transaction-related costs such as brokerage, taxes, and advisory fees.

Price Flexibility and Promoter Holding

The board has retained the flexibility to revise the buyback price upward, and correspondingly reduce the number of shares to be repurchased, up to one working day before the record date, keeping the total outlay unchanged at ₹800 crore.

As of December 31, 2025, promoters and promoter group entities collectively held 51.82% of Aurobindo Pharma's 58,08,01,623 equity shares. The revised shareholding pattern following the buyback will be determined once the process concludes.

About Aurobindo Pharma

Founded in 1986 and headquartered in Hyderabad, Aurobindo Pharma is an integrated global pharmaceutical company engaged in the development, manufacturing, and marketing of generic medicines, injectables, and active pharmaceutical ingredients (APIs). The company operates across more than 150 countries through an extensive network of manufacturing facilities and international subsidiaries.

Aurobindo Pharma currently carries a market capitalisation of approximately ₹77,064 crore. On the stock performance front, shares have delivered returns of 20.92% over one year, 18.88% over two years, and a striking 149.62% over the past three years, reflecting sustained investor confidence in the company's fundamentals.

What This Means for Investors

Share buybacks are generally viewed as a positive signal; they indicate that management believes the stock is undervalued and that the company has sufficient free cash flow to return capital to shareholders. For investors who participate in the tender offer, the ₹1,475 price offers an exit at a premium to the prevailing market price. For those who choose to hold, a smaller share count post-buyback improves earnings per share (EPS) and return ratios over time.

This is Aurobindo Pharma's second major buyback in quick succession. In July 2024, the company had approved a ₹750 crore repurchase at ₹1,460 per share via the same tender offer route. The latest announcement at a higher price and larger size signals growing confidence in the company's financial health and cash generation ability heading into the new financial year.

1. The Hindu – Business
   https://www.thehindu.com/business/Industry/aurobindo-pharma-board-apporves-800-cr-share-buyback-plan/article70829179.ece
2. DSIJ (Dalal Street Investment Journal)
   https://insights.dsij.in/dsijarticledetail/buyback-alert-divis-laboratories-competitor-approves-rs-800-crore-share-buyback-id021-56339
3. ScanX Trade – Board Meeting Intimation
   https://scanx.trade/stock-market-news/companies/aurobindo-pharma-board-meeting-scheduled-for-april-6-2026-to-consider-share-buyback-proposal/36550466
4. Business Standard – 2024 Buyback Reference
   https://www.business-standard.com/companies/news/aurobindo-pharma-board-approves-share-buyback-plan-worth-rs-750-cr-124071800636_1.html
5. Aurobindo Pharma Official Website
   https://www.aurobindo.com

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investments in the securities market are subject to market risks. Please read all related documents carefully and consult a qualified financial advisor before investing.